MED17

Across TCGA pan-cancer cohorts, MED17 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated MED17 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher MED17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MED17 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, LUAD, and UCEC are the cancer types where MED17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.121	0.829	<.001	48	view →
LUAD	OS	Median	All	0.090	0.788	<.001	20	view →
UCEC	OS	Median	II,III,IV	1.000	0.319	.006	18	view →
STAD	OS	Median	All	0.228	0.729	.010	15	view →
BRCA	OS	Median	All	0.410	0.924	<.001	12	view →
KICH	DFS	Median	All	0.162	0.862	.014	10	view →
BLCA	DFS	Median	IV	0.077	0.476	<.001	6	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MED17–CESC (OS)

Open the CESC breakdown →